Overcoming Diseases by International Collaboration | Shinya Yamanaka, MD, PhD

Since induced pluripotent stem (iPS) cells were first reported in 2006, we have seen great research advancement; iPS cells have been used as a powerful tool in basic science to elucidate mysteries of life, as well as in medical applications such as regenerative medicine and drug development. It is worth noting that clinical trials are ongoing for some diseases, including Parkinson’s disease, heart failure, and ALS, and many more are expected to follow. In addition, iPS cell technology is demonstrating its potential to fight against another huge challenge, COVID-19, contributing to a better understanding of its pathology and the development of treatments.
Making harmonious collaborations is vital to accelerate disruptive innovation for overcoming diseases. With that aim, the “iPS Cell Research Center at Gladstone Institutes” was launched in 2019 under the Kyoto University’s On-site Laboratory initiative, and we envision the expansion of our borderless collaboration to develop the next game-changing research.
Shinya Yamanaka, MD, PhD, is a senior investigator at Gladstone Institutes and director and professor at CiRA, Kyoto University
This talk was given at the Kickoff Symposium for the iPS Cell Research Center at Gladstone Institutes on February 8, 2021. This session was chaired and moderated by Hirohide Saito, PhD, deputy director and professor at CiRA, Kyoto University

[@joeschmoe5583]

Thank you for this interview! Especially for us english-speaking viewers!